Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205
December 17, 2024
Spruce Biosciences, a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, announced topline